{
    "organizations": [],
    "uuid": "9f81c22887d213b78adbdaa6d26e2f65c70cec67",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-zogenix-announces-presentation-of/brief-zogenix-announces-presentation-of-new-efficacy-and-safety-data-from-its-firstpivotal-phase-3-clinical-trial-of-zx008-in-dravet-syndrome-idUSASC09XB1",
    "ord_in_thread": 0,
    "title": "BRIEF-Zogenix Announces Presentation Of New Efficacy And Safety Data From Its First Pivotal Phase 3 Clinical Trial Of ZX008 In Dravet Syndrome",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 25 (Reuters) - Zogenix Inc:\n* ZOGENIX ANNOUNCES PRESENTATION OF NEW EFFICACY AND SAFETY DATA FROM ITS FIRST PIVOTAL PHASE 3 CLINICAL TRIAL OF ZX008 IN DRAVET SYNDROME\n* ZOGENIX - PATIENTS ON ZX008 ACHIEVED SIGNIFICANT, CLINICALLY MEANINGFUL REDUCTION IN TOTAL SEIZURE FREQUENCY COMPARED TO THOSE ON PLACEBO Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-25T20:08:00.000+03:00",
    "crawled": "2018-04-26T20:06:44.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "zogenix",
        "inc",
        "zogenix",
        "announces",
        "presentation",
        "new",
        "efficacy",
        "safety",
        "data",
        "first",
        "pivotal",
        "phase",
        "clinical",
        "trial",
        "zx008",
        "dravet",
        "syndrome",
        "zogenix",
        "patient",
        "zx008",
        "achieved",
        "significant",
        "clinically",
        "meaningful",
        "reduction",
        "total",
        "seizure",
        "frequency",
        "compared",
        "placebo",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}